Nanexa
Nanexa receives Japanese patent approval for specific PharmaShell structure
The approval strengthens Nanexa’s patent portfolio, with additional patent applications filed in other strategically important countries
Nanexa announces that a key patent application has been granted in Japan and been given the patent number JP7733651B2. The patented invention concerns a specific structure in the shell used in its PharmaShell platform.
Patent applications for the same patent family have also been filed in commercially and strategically important countries, including the US and in Europe. The patent is expected to last until at least December 2039.
In addition, in recent months, Nanexa has filed three new patent applications covering innovative improvements to the PharmaShell technology that the company considers to be both essential and enabling. These cases are expected to significantly strengthen the patent portfolio and, if granted, are expected to provide additional layers of protection for the technology until 2046.
Anders Johansson, Co-founder and Head of Intellectual Property at Nanexa, comments:
“The advantage of being front-runners in a particular field is that you are best placed to solve the field's technical challenges through innovation. We have always been, and continue to be, diligent in safeguarding all new inventions strategically and comprehensively. Over the years, this has allowed us to build a broad and strong patent portfolio.”
Datum | 2025-09-22, kl 08:00 |
Källa | MFN |